Biotheus Enters into an Agreement with Alligator Bioscience to Develop Bispecific Molecules in Greater China

 Biotheus Enters into an Agreement with Alligator Bioscience to Develop Bispecific Molecules in Greater China

Biotheus Enters into an Antibody Agreement with Alligator Bioscience in Greater China

Shots:

  • Alligator to receive ~52M in development milestones including $1M up front, $90M as option fee and royalties on sales and share of sub-license revenue. Biotheus to get right to an antibody from ALLIGATOR-GOLD to develop up to three bispecific molecules in Greater China with an option to expand the license for global rights
  • The agreement provides entrance to the Alligator’s antibody library in China and proven its expertise in developing antibodies against TNFR family members
  • ALLIGATOR-GOLD is a human Ab library containing 60B+ unique antibody fragments and has five leading clinical and preclinical drug candidates including ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144

Click here to­ read full press release/ article | Ref: PRnewswire| Image: Camegie

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post